Supporting Pharmaceutical Studies for FDA Submissions: Diversifying the Drug Monitoring Laboratory (Tdm Conference) Supporting Pharmaceutical Studies for FDA Submissions: Diversifying the Drug Monitoring Laboratory (Tdm Conference)

Supporting Pharmaceutical Studies for FDA Submissions: Diversifying the Drug Monitoring Laboratory (Tdm Conference‪)‬

Clinical Chemistry 1998, Feb, 44, 2

    • 2,99 €
    • 2,99 €

Description de l’éditeur

There is a rigorous review process associated with bringing a new pharmaceutical product to the consumer market in the US. Introduction of a new drug or a new clinical application for a drug requires demonstration to the US Food and Drug Administration (FDA) that a beneficial effect can be clearly associated with that drug; side effects and toxicities must be declared with statements from medical experts, indicating that the clinical benefits outweigh any known detrimental effects; and the pharmacokinetics of the drug must be defined as technology allows. The process of filing with the FDA to obtain approval to market the drug is known as a New Drug Application (NDA). (1) For generic drugs, the process of applying for approval to market is described as an Abbreviated New Drug Application (ANDA), "abbreviated" in that the application does not require information supporting the clinical efficacy because that has already been demonstrated. Information describing the pharmacokinetic characteristics of the proposed generic form of the drug must be submitted to document that the generic form is biologically equivalent to the proprietary product.

GENRE
Science et nature
SORTIE
1998
1 février
LANGUE
EN
Anglais
LONGUEUR
10
Pages
ÉDITIONS
American Association for Clinical Chemistry, Inc.
DÉTAILS DU FOURNISSEUR
The Gale Group, Inc., a Delaware corporation and an affiliate of Cengage Learning, Inc.
TAILLE
182,7
Ko
Principles of Biomedical Sciences and Industry Principles of Biomedical Sciences and Industry
2022
The Role of the Study Director in Nonclinical Studies The Role of the Study Director in Nonclinical Studies
2014
Genetic Testing and the Clinical Laboratory Improvement Amendments of 1988: Present and Future (Clinical Chemistry Forum) Genetic Testing and the Clinical Laboratory Improvement Amendments of 1988: Present and Future (Clinical Chemistry Forum)
1999
BioWatch PCR Assays BioWatch PCR Assays
2015
Laboratory-Related Outcomes in Healthcare (Beckman Conference) (Clinical Report) Laboratory-Related Outcomes in Healthcare (Beckman Conference) (Clinical Report)
2001
Immunoassay Standardization: Is It Possible, Who Is Responsible, Who Is Capable?(Opinion) (Clinical Report) Immunoassay Standardization: Is It Possible, Who Is Responsible, Who Is Capable?(Opinion) (Clinical Report)
2001
Percent Free Prostate-Specific Antigen in Assessing the Probability of Prostate Cancer Under Optimal Analytical Conditions (Enzymes and Protein Markers) Percent Free Prostate-Specific Antigen in Assessing the Probability of Prostate Cancer Under Optimal Analytical Conditions (Enzymes and Protein Markers)
1998
Distribution of Adiponectin, Leptin, And Metabolic Correlates of Insulin Resistance: A Longitudinal Study in British Children; 1: Prepuberty (Earlybird 15) (Endocrinology and Metabolism) (Clinical Report) Distribution of Adiponectin, Leptin, And Metabolic Correlates of Insulin Resistance: A Longitudinal Study in British Children; 1: Prepuberty (Earlybird 15) (Endocrinology and Metabolism) (Clinical Report)
2008
The MALDI-TOF Mass Spectrometric View of the Plasma Proteome and Peptidome. The MALDI-TOF Mass Spectrometric View of the Plasma Proteome and Peptidome.
2006
Interlaboratory Comparison of Fetal Male DNA Detection from Common Maternal Plasma Samples by Real-Time Pcr (Molecular Diagnostics and Genetics) Interlaboratory Comparison of Fetal Male DNA Detection from Common Maternal Plasma Samples by Real-Time Pcr (Molecular Diagnostics and Genetics)
2004
Ghrelin, Leptin, IGF-1, IGFBP-3, and Insulin Concentrations at Birth: Is There a Relationship with Fetal Growth and Neonatal Anthropometry?(Pediatric Clinical Chemistry) Ghrelin, Leptin, IGF-1, IGFBP-3, and Insulin Concentrations at Birth: Is There a Relationship with Fetal Growth and Neonatal Anthropometry?(Pediatric Clinical Chemistry)
2008
Association of Increased Ferritin with Premature Coronary Stenosis in Men (Lipids, Lipoproteins, And Cardiovascular Risk Factors) Association of Increased Ferritin with Premature Coronary Stenosis in Men (Lipids, Lipoproteins, And Cardiovascular Risk Factors)
2001